nach oben

Current Psychiatry Reports

Erschienen in:

01.09.2017 | Genetic Disorders (F Goes, Section Editor)

Genetics of Schizophrenia: Ready to Translate?

verfasst von: Claire Foley, Aiden Corvin, Shigeki Nakagome

Erschienen in: Current Psychiatry Reports | Ausgabe 9/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

This is an era where we have significantly advanced the understanding of the genetic architecture of schizophrenia. In this review, we consider how this knowledge may translate into advances that will improve patient care.

Recent Findings

Large-scale genome-wide association studies (GWAS) have identified more than a hundred loci each making a small contribution to illness risk. Meta-analysis of copy number variants (CNVs) in the Psychiatric Genomics Consortium (PGC) dataset has confirmed that some variants have a moderate or large impact on risk, although these are rare in the population. Genome sequencing advances allow a much more comprehensive evaluation of genomic variation. We describe the key findings from whole exome studies to date. These studies are happening against a backdrop of growing understanding of the regulation and expression of genes and better functional tools to investigate molecular mechanisms in model systems.

Summary

We provide an overview of how recent approaches in schizophrenia genetics are converging and consider how they could impact on diagnostics, the development of personalized medicine, and drug discovery.

Hegarty JD, Baldessarini RJ, Tohen M, Waternaux C, Oepen G. One hundred years of schizophrenia: a meta-analysis of the outcome literature. Am J Psychiatry. 1994;151(10):1409–16.CrossRefPubMed

Matheson S, Shepherd A, Pinchbeck R, Laurens K, Carr V. Childhood adversity in schizophrenia: a systematic meta-analysis. Psychol Med. 2013;43(2):225.CrossRefPubMed

Cantor-Graae E, Selten J-P. Schizophrenia and migration: a meta-analysis and review. Am J Psychiatr. 2005;162(1):12–24.CrossRefPubMed

Tandon R, Keshavan MS, Nasrallah HA. Schizophrenia, "just the facts": what we know in 2008 part 1: overview. Schizophr Res. 2008;100(1–3):4–19. doi:10.1016/j.schres.2008.01.022.CrossRefPubMed

Miyamoto S, Miyake N, Jarskog LF, Fleischhacker WW, Lieberman JA. Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents. Mol Psychiatry. 2012;17(12):1206–27. doi:10.1038/mp.2012.47.CrossRefPubMed

Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet (London, England). 2013;382(9896):951–62. doi:10.1016/s0140-6736(13)60733-3.CrossRef

Tiihonen J, Lonnqvist J, Wahlbeck K, Klaukka T, Niskanen L, Tanskanen A, et al. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet. 2009;374(9690):620–7. doi:10.1016/s0140-6736(09)60742-x.CrossRefPubMed

Kamb A, Harper S, Stefansson K. Human genetics as a foundation for innovative drug development. Nat Biotechnol. 2013;31(11):975–8. doi:10.1038/nbt.2732.CrossRefPubMed

• Nioi P, Sigurdsson A, Thorleifsson G, Helgason H, Agustsdottir AB, Norddahl GL, et al. Variant ASGR1 associated with a reduced risk of coronary artery disease. N Engl J Med. 2016;374(22):2131–41. doi:10.1056/NEJMoa1508419. This whole-genome sequencing study identified a deletion leading to inactivation of ASGR1, associated with reduced levels of non-HDL cholesterol and a resultant reduced risk of coronary artery disease. CrossRefPubMed

10.

Welter D, MacArthur J, Morales J, Burdett T, Hall P, Junkins H, et al. The NHGRI GWAS catalog, a curated resource of SNP-trait associations. Nucleic Acids Res. 2014;42(Database issue):6.

11.

• Schizophrenia Working Group of the Psychiatric Genomics C. Biological insights from 108 schizophrenia-associated genetic loci. Nature. 2014;511(7510):421–7. doi:10.1038/nature13595. This paper reported on an extensive GWAS analysis on schizophrenia, including data on up to 36,989 cases and 113,075 controls. 108 independent genomic risk loci associated with schizophrenia were identified. http://www.nature.com/nature/journal/v511/n7510/abs/nature13595.html#supplementary-information CrossRef

12.

Psychiatric genome-wide association study analyses implicate neuronal, immune and histone pathways. Nat Neurosci. 2015;18(2):199–209.

13.

Corvin A, Morris DW. Genome-wide association studies: findings at the major histocompatibility complex locus in psychosis. Biol Psychiatry. 2014;75(4):276–83. doi:10.1016/j.biopsych.2013.09.018.CrossRefPubMed

14.

Shi J, Levinson DF, Duan J, Sanders AR, Zheng Y, Pe'er I, et al. Common variants on chromosome 6p22.1 are associated with schizophrenia. Nature. 2009;460(7256):753–7. doi:10.1038/nature08192.PubMedPubMedCentral

15.

Genome-wide association study implicates HLA-C*01:02 as a risk factor at the major histocompatibility complex locus in schizophrenia. Biol Psychiatry. 2012;72(8):620–8. doi:10.1016/j.biopsych.2012.05.035.

16.

Genome-wide association study identifies five new schizophrenia loci. Nature genetics. 2011;43(10):969–76. doi:10.1038/ng.940.

17.

Morris DW, Pearson RD, Cormican P, Kenny EM, O'Dushlaine CT, Lemieux Perreault L-P, et al. An inherited duplication at the gene p21 protein-activated kinase 7 (PAK7) is a risk factor for psychosis. Hum Mol Genet. 2014; doi:10.1093/hmg/ddu025.

18.

• Sekar A, Bialas AR, de Rivera H, Davis A, Hammond TR, Kamitaki N, et al. Schizophrenia risk from complex variation of complement component 4. Nature. 2016;530(7589):177–83. doi:10.1038/nature16549. This study examined the association of schizophrenia with variation in the MHC locus, identifying a key role of excessive complement component 4 activity, possibly resulting in the synapse loss observed in schizophrenia CrossRefPubMedPubMedCentral

19.

Loh PR, Bhatia G, Gusev A, Finucane HK, Bulik-Sullivan BK, Pollack SJ, et al. Contrasting genetic architectures of schizophrenia and other complex diseases using fast variance-components analysis. Nat Genet. 2015;47(12):1385–92. doi:10.1038/ng.3431.CrossRefPubMedPubMedCentral

20.

Gratten J, Wray NR, Keller MC, Visscher PM. Large-scale genomics unveils the genetic architecture of psychiatric disorders. Nat Neurosci. 2014;17(6):782–90. doi:10.1038/nn.3708.CrossRefPubMedPubMedCentral

21.

Pharoah PD, Antoniou A, Bobrow M, Zimmern RL, Easton DF, Ponder BA. Polygenic susceptibility to breast cancer and implications for prevention. Nat Genet. 2002;31(1):33–6. doi:10.1038/ng853.CrossRefPubMed

22.

Chatterjee N, Shi J, Garcia-Closas M. Developing and evaluating polygenic risk prediction models for stratified disease prevention. Nat Rev Genet. 2016;17(7):392–406. doi:10.1038/nrg.2016.27.CrossRefPubMed

23.

Yang J, Benyamin B, McEvoy BP, Gordon S, Henders AK, Nyholt DR, et al. Common SNPs explain a large proportion of the heritability for human height. Nat Genet. 2010;42(7):565–9.CrossRefPubMedPubMedCentral

24.

Iafrate AJ, Feuk L, Rivera MN, Listewnik ML, Donahoe PK, Qi Y, et al. Detection of large-scale variation in the human genome. Nat Genet. 2004;36(9):949–51. doi:10.1038/ng1416.CrossRefPubMed

25.

Sebat J, Lakshmi B, Troge J, Alexander J, Young J, Lundin P, et al. Large-scale copy number polymorphism in the human genome. Science (New York, NY). 2004;305(5683):525–8. doi:10.1126/science.1098918.CrossRef

26.

Malhotra D, Sebat J. CNVs: harbingers of a rare variant revolution in psychiatric genetics. Cell. 2012;148(6):1223–41. doi:10.1016/j.cell.2012.02.039.CrossRefPubMedPubMedCentral

27.

Pulver AE, Nestadt G, Goldberg R, Shprintzen RJ, Lamacz M, Wolyniec PS, et al. Psychotic illness in patients diagnosed with velo-cardio-facial syndrome and their relatives. J Nerv Ment Dis. 1994;182(8):476–8.CrossRefPubMed

28.

Walsh T, McClellan JM, McCarthy SE, Addington AM, Pierce SB, Cooper GM, et al. Rare structural variants disrupt multiple genes in neurodevelopmental pathways in schizophrenia. Science (New York, NY). 2008;320(5875):539–43. doi:10.1126/science.1155174.CrossRef

29.

Rare chromosomal deletions and duplications increase risk of schizophrenia. Nature. 2008;455(7210):237–41. doi:http://www.nature.com/nature/journal/v455/n7210/suppinfo/nature07239_S1.html.

30.

• Contribution of copy number variants to schizophrenia from a genome-wide study of 41,321 subjects. Nat Genet. 2017;49(1):27–35. doi:10.1038/ng.3725. This study found genome-wide significant evidence for eight CNV loci contributing to schizophrenia risk with suggestive support for a further eight candidate susceptibility and protective loci

31.

Stefansson H, Rujescu D, Cichon S, Pietilainen OP, Ingason A, Steinberg S, et al. Large recurrent microdeletions associated with schizophrenia. Nature. 2008;455(7210):232–6. doi:10.1038/nature07229.CrossRefPubMedPubMedCentral

32.

Rees E, Kendall K, Pardinas AF, Legge SE, Pocklington A, Escott-Price V, et al. Analysis of intellectual disability copy number variants for association with schizophrenia. JAMA psychiatry. 2016;73(9):963–9. doi:10.1001/jamapsychiatry.2016.1831.CrossRefPubMed

33.

Kirov G, Pocklington AJ, Holmans P, Ivanov D, Ikeda M, Ruderfer D, et al. De novo CNV analysis implicates specific abnormalities of postsynaptic signalling complexes in the pathogenesis of schizophrenia. Mol Psychiatry. 2012;17(2):142–53. doi:10.1038/mp.2011.154.CrossRefPubMed

34.

Kirov G. CNVs in neuropsychiatric disorders. Hum Mol Genet. 2015;24(R1):R45–9. doi:10.1093/hmg/ddv253.CrossRefPubMed

35.

Morris DW, Pearson RD, Cormican P, Kenny EM, O'Dushlaine CT, Perreault LP, et al. An inherited duplication at the gene p21 protein-activated kinase 7 (PAK7) is a risk factor for psychosis. Hum Mol Genet. 2014;23(12):3316–26. doi:10.1093/hmg/ddu025.CrossRefPubMedPubMedCentral

36.

Rujescu D, Ingason A, Cichon S, Pietilainen OP, Barnes MR, Toulopoulou T, et al. Disruption of the neurexin 1 gene is associated with schizophrenia. Hum Mol Genet. 2009;18(5):988–96. doi:10.1093/hmg/ddn351.CrossRefPubMed

37.

Rees E, Walters JT, Chambert KD, O'Dushlaine C, Szatkiewicz J, Richards AL, et al. CNV analysis in a large schizophrenia sample implicates deletions at 16p12.1 and SLC1A1 and duplications at 1p36.33 and CGNL1. Hum Mol Genet. 2014;23(6):1669–76. doi:10.1093/hmg/ddt540.CrossRefPubMed

38.

• Kirov G, Rees E, Walters JT, Escott-Price V, Georgieva L, Richards AL, et al. The penetrance of copy number variations for schizophrenia and developmental delay. Biol Psychiatry. 2014;75(5):378–85. doi:10.1016/j.biopsych.2013.07.022. This study estimated total penetrance of thirteen schizophrenia-associated CNVs for neurodevelopmental disorders including SCZ, DD, ASD or a congenital malformation, to be high (ranging between 10.6%-100%), with significant implications for genetic counselling CrossRefPubMed

39.

Tansey KE, Rees E, Linden DE, Ripke S, Chambert KD, Moran JL, et al. Common alleles contribute to schizophrenia in CNV carriers. Mol Psychiatry. 2016;21(8):1085–9. doi:10.1038/mp.2015.143.CrossRefPubMed

40.

Liu P, Carvalho CM, Hastings PJ, Lupski JR. Mechanisms for recurrent and complex human genomic rearrangements. Curr Opin Genet Dev. 2012;22(3):211–20. doi:10.1016/j.gde.2012.02.012.CrossRefPubMedPubMedCentral

41.

MacArthur DG, Balasubramanian S, Frankish A, Huang N, Morris J, Walter K, et al. A systematic survey of loss-of-function variants in human protein-coding genes. Science (New York, NY). 2012;335(6070):823–8. doi:10.1126/science.1215040.CrossRef

42.

Mägi R, Asimit JL, Day-Williams AG, Zeggini E, Morris AP. Genome-wide association analysis of imputed rare variants: application to seven common complex diseases. Genet Epidemiol. 2012;36(8):785–96. doi:10.1002/gepi.21675.PubMedPubMedCentral

43.

de Ligt J, Willemsen MH, van Bon BW, Kleefstra T, Yntema HG, Kroes T, et al. Diagnostic exome sequencing in persons with severe intellectual disability. N Engl J Med. 2012;367(20):1921–9. doi:10.1056/NEJMoa1206524.CrossRefPubMed

44.

Rauch A, Wieczorek D, Graf E, Wieland T, Endele S, Schwarzmayr T, et al. Range of genetic mutations associated with severe non-syndromic sporadic intellectual disability: an exome sequencing study. Lancet. 2012;380(9854):1674–82. doi:10.1016/s0140-6736(12)61480-9.CrossRefPubMed

45.

O'Roak BJ, Vives L, Fu W, Egertson JD, Stanaway IB, Phelps IG, et al. Multiplex targeted sequencing identifies recurrently mutated genes in autism spectrum disorders. Science (New York, NY). 2012;338(6114):1619–22. doi:10.1126/science.1227764.CrossRef

46.

De Rubeis S, He X, Goldberg AP, Poultney CS, Samocha K, Ercument Cicek A, et al. Synaptic, transcriptional and chromatin genes disrupted in autism. Nature. 2014;515(7526):209–15. doi:10.1038/nature13772.CrossRefPubMedPubMedCentral

47.

Allen AS, Berkovic SF, Cossette P, Delanty N, Dlugos D, Eichler EE, et al. De novo mutations in epileptic encephalopathies. Nature. 2013;501(7466):217–21. doi:10.1038/nature12439.CrossRefPubMed

48.

Singh T, Kurki MI, Curtis D, Purcell SM, Crooks L, McRae J, et al. Rare loss-of-function variants in SETD1A are associated with schizophrenia and developmental disorders. Nat Neurosci. 2016;19(4):571–7. doi:10.1038/nn.4267.CrossRefPubMed

49.

Zuk O, Schaffner SF, Samocha K, Do R, Hechter E, Kathiresan S, et al. Searching for missing heritability: designing rare variant association studies. Proc Natl Acad Sci U S A. 2014;111(4):E455–64. doi:10.1073/pnas.1322563111.CrossRefPubMedPubMedCentral

50.

• Purcell SM, Moran JL, Fromer M, Ruderfer D, Solovieff N, Roussos P, et al. A polygenic burden of rare disruptive mutations in schizophrenia. Nature. 2014;506(7487):185–90. doi:10.1038/nature12975. This paper introduces the polygene score method and its application to schizophrenia CrossRefPubMedPubMedCentral

51.

Fromer M, Pocklington AJ, Kavanagh DH, Williams HJ, Dwyer S, Gormley P, et al. De novo mutations in schizophrenia implicate synaptic networks. Nature. 2014;506(7487):179–84. doi:10.1038/nature12929.CrossRefPubMedPubMedCentral

52.

53.

Iossifov I, O’Roak BJ, Sanders SJ, Ronemus M, Krumm N, Levy D, et al. The contribution of de novo coding mutations to autism spectrum disorder. Nature. 2014;515(7526):216–21.CrossRefPubMedPubMedCentral

54.

• Genovese G, Fromer M, Stahl EA, Ruderfer DM, Chambert K, Landen M, et al. Increased burden of ultra-rare protein-altering variants among 4,877 individuals with schizophrenia. Nat Neurosci. 2016;19(11):1433–41. doi:10.1038/nn.4402. This study explored the role of rare coding mutations in schizophrenia and identified that most dURVs contributing to the disorder appeared to be inherited and enriched in brain-specific genes. The findings provide evidence of a general synaptic dysfunction in the pathogenesis of schizophrenia CrossRefPubMedPubMedCentral

55.

Akil H, Brenner S, Kandel E, Kendler KS, King MC, Scolnick E, et al. Medicine. The future of psychiatric research: genomes and neural circuits. Science (New York, NY). 2010;327(5973):1580–1. doi:10.1126/science.1188654.CrossRef

56.

Corvin A, Sullivan PF. What next in schizophrenia genetics for the psychiatric genomics consortium? Schizophr Bull. 2016;42(3):538–41.CrossRefPubMedPubMedCentral

57.

O'Byrne JJ, Lynch SA, Treacy EP, King MD, Betts DR, Mayne PD, et al. Unexplained developmental delay/learning disability: guidelines for best practice protocol for first line assessment and genetic/metabolic/radiological investigations. Ir J Med Sci. 2016;185(1):241–8. doi:10.1007/s11845-015-1284-7.CrossRefPubMed

58.

Schaefer GB, Mendelsohn NJ. Clinical genetics evaluation in identifying the etiology of autism spectrum disorders: 2013 guideline revisions. Genet Med. 2013;15(5):399–407.CrossRefPubMed

59.

Kendall KM, Rees E, Escott-Price V, Einon M, Thomas R, Hewitt J, et al. Cognitive performance among carriers of pathogenic copy number variants: analysis of 152,000 UK biobank subjects. Biol Psychiatry. 2016; doi:10.1016/j.biopsych.2016.08.014.

60.

Stefansson H, Meyer-Lindenberg A, Steinberg S, Magnusdottir B, Morgen K, Arnarsdottir S, et al. CNVs conferring risk of autism or schizophrenia affect cognition in controls. Nature. 2014;505(7483):361–6. doi:10.1038/nature12818.CrossRefPubMed

61.

Miles JH, Takahashi TN, Bagby S, Sahota PK, Vaslow DF, Wang CH, et al. Essential versus complex autism: definition of fundamental prognostic subtypes. Am J Med Genet A. 2005;135(2):171–80. doi:10.1002/ajmg.a.30590.CrossRefPubMed

62.

Rajarajan P, Gil SE, Brennand KJ, Akbarian S. Spatial genome organization and cognition. Nat Rev Neurosci. 2016;17(11):681–91. doi:10.1038/nrn.2016.124.CrossRefPubMedPubMedCentral

63.

Cong L, Ran FA, Cox D, Lin S, Barretto R, Habib N, et al. Multiplex genome engineering using CRISPR/Cas systems. Science (New York, NY). 2013;339(6121):819–23. doi:10.1126/science.1231143.CrossRef

64.

Han K, Jeng EE, Hess GT, Morgens DW, Li A, Bassik MC. Synergistic drug combinations for cancer identified in a CRISPR screen for pairwise genetic interactions. Nat Biotechnol. 2017; doi:10.1038/nbt.3834.

65.

Lee IS, Carvalho CM, Douvaras P, Ho S-M, Hartley BJ, Zuccherato LW, et al. Characterization of molecular and cellular phenotypes associated with a heterozygous CNTNAP2 deletion using patient-derived hiPSC neural cells. npj Schizophrenia. 2015;1:15019.CrossRefPubMedPubMedCentral

66.

Wen Z, Nguyen HN, Guo Z, Lalli MA, Wang X, Su Y, et al. Synaptic dysregulation in a human iPS cell model of mental disorders. Nature. 2014;515(7527):414–8. doi:10.1038/nature13716. http://www.nature.com/nature/journal/v515/n7527/abs/nature13716.html#supplementary-information CrossRefPubMedPubMedCentral

67.

Kim CK, Adhikari A, Deisseroth K. Integration of optogenetics with complementary methodologies in systems neuroscience. Nat Rev Neurosci. 2017;18(4):222–35.CrossRefPubMed

68.

Sekar A, Bialas AR, de Rivera H, Davis A, Hammond TR, Kamitaki N, et al. Schizophrenia risk from complex variation of complement component 4. Nature. 2016; doi:10.1038/nature16549.

69.

Garey LJ, Ong WY, Patel TS, Kanani M, Davis A, Mortimer AM, et al. Reduced dendritic spine density on cerebral cortical pyramidal neurons in schizophrenia. J Neurol Neurosurg Psychiatry. 1998;65(4):446–53.CrossRefPubMedPubMedCentral

70.

Glantz LA, Lewis DA. Decreased dendritic spine density on prefrontal cortical pyramidal neurons in schizophrenia. Arch Gen Psychiatry. 2000;57(1):65–73.CrossRefPubMed

71.

Glausier JR, Lewis DA. Dendritic spine pathology in schizophrenia. Neuroscience. 2013;251:90–107. doi:10.1016/j.neuroscience.2012.04.044.CrossRefPubMed

72.

• Krey JF, Pasca SP, Shcheglovitov A, Yazawa M, Schwemberger R, Rasmusson R, et al. Timothy syndrome is associated with activity-dependent dendritic retraction in rodent and human neurons. Nat Neurosci. 2013;16(2):201–9. doi:10.1038/nn.3307. This study examined the point mutation in the calcium channel CACNA1C causing Timothy syndrome (a neurodevelopmental disorder) in iPSC-derived cortical neurons and identified activity-dependent dendritic retraction in neurons, providing insights into the cellular basis of Timothy syndrome and potentially other neurodevelopmental disorders CrossRefPubMedPubMedCentral

73.

Zhang JP, Lencz T, Malhotra AK. D2 receptor genetic variation and clinical response to antipsychotic drug treatment: a meta-analysis. Am J Psychiatry. 2010;167(7):763–72. doi:10.1176/appi.ajp.2009.09040598.CrossRefPubMedPubMedCentral

74.

Zhang J-P, Malhotra AK. Pharmacogenetics of antipsychotics: recent progress and methodological issues. Expert Opin Drug Metab Toxicol. 2013;9(2):183–91.CrossRefPubMed

75.

Lieberman JA, Yunis J, Egea E, Canoso RT, Kane JM, Yunis EJ. HLA-B38, DR4, DQw3 and clozapine-induced agranulocytosis in Jewish patients with schizophrenia. Arch Gen Psychiatry. 1990;47(10):945–8.CrossRefPubMed

76.

Yunis JJ, Corzo D, Salazar M, Lieberman JA, Howard A, Yunis EJ. HLA associations in clozapine-induced agranulocytosis. Blood. 1995;86(3):1177–83.PubMed

77.

Athanasiou MC, Dettling M, Cascorbi I, Mosyagin I, Salisbury BA, Pierz KA, et al. Candidate gene analysis identifies a polymorphism in HLA-DQB1 associated with clozapine-induced agranulocytosis. The Journal of clinical psychiatry. 2011;72(4):458–63.CrossRefPubMed

78.

Zhang J-P, Malhotra AK. Pharmacogenetics and antipsychotics: therapeutic efficacy and side effects prediction. Expert Opin Drug Metab Toxicol. 2011;7(1):9–37. doi:10.1517/17425255.2011.532787.CrossRefPubMedPubMedCentral

79.

Riglin L, Collishaw S, Richards A, Thapar AK, Maughan B, O'Donovan MC, et al. Schizophrenia risk alleles and neurodevelopmental outcomes in childhood: a population-based cohort study. The lancet Psychiatry. 2017;4(1):57–62. doi:10.1016/s2215-0366(16)30406-0.CrossRefPubMed

80.

Ahn K, An SS, Shugart YY, Rapoport JL. Common polygenic variation and risk for childhood-onset schizophrenia. Mol Psychiatry. 2016;21(1):94–6. doi:10.1038/mp.2014.158.CrossRefPubMed

81.

Meltzer HY. Treatment-resistant schizophrenia—the role of clozapine. Curr Med Res Opin. 1997;14(1):1–20. doi:10.1185/03007999709113338.CrossRefPubMed

82.

Nielsen J, Nielsen RE, Correll CU. Predictors of clozapine response in patients with treatment-refractory schizophrenia: results from a Danish register study. J Clin Psychopharmacol. 2012;32(5):678–83. doi:10.1097/JCP.0b013e318267b3cd.CrossRefPubMed

83.

Frank J, Lang M, Witt SH, Strohmaier J, Rujescu D, Cichon S, et al. Identification of increased genetic risk scores for schizophrenia in treatment-resistant patients. Mol Psychiatry. 2015;20(2):150–1. doi:10.1038/mp.2014.56.CrossRefPubMed

Titel: Genetics of Schizophrenia: Ready to Translate?
verfasst von: Claire Foley
Aiden Corvin
Shigeki Nakagome
Publikationsdatum: 01.09.2017
Verlag: Springer US
Erschienen in: Current Psychiatry Reports / Ausgabe 9/2017
Print ISSN: 1523-3812
Elektronische ISSN: 1535-1645
DOI: https://doi.org/10.1007/s11920-017-0807-5

Neu im Fachgebiet Psychiatrie

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

23.04.2024 Depression antepartal oder postpartal Nachrichten

Bislang gibt es kein Medikament zur Prävention von Wochenbettdepressionen. Das Injektionsanästhetikum Esketamin könnte womöglich diese Lücke füllen.

„Psychotherapie ist auch bei sehr alten Menschen hochwirksam!“

22.04.2024 DGIM 2024 Kongressbericht

Die Kombination aus Medikamenten und Psychotherapie gilt als effektivster Ansatz bei Depressionen. Das ist bei betagten Menschen nicht anders, trotz Besonderheiten.

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

22.04.2024 DGIM 2024 Nachrichten

Um Menschen nach der Flucht aus einem Krisengebiet bestmöglich medizinisch betreuen zu können, ist es gut zu wissen, welche Erkrankungen im jeweiligen Herkunftsland häufig sind. Dabei hilft eine Internetseite der CDC (Centers for Disease Control and Prevention).

Update Psychiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 9/2017

Neurocognitive Treatments for Eating Disorders and Obesity

Dementia Caregiver Burden: a Research Update and Critical Analysis

A Skill Set for Supporting Displaced Children in Psychological Recovery After Disasters

Valproic Acid in Women and Girls of Childbearing Age